Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes


Preclinical data provide evidence for synergism between ketogenic diets (KDs) and other oncological therapies. The aim of this systematic review was to summarize data from clinical studies that have tested KDs along with other treatments used within medical oncology. The PubMed database was searched using the key words "ketogenic" AND ("cancer" OR "glioblastoma"). A secondary search was conducted by screening the reference lists of relevant articles on this topic. Relevant studies for this review were defined as studies in which KDs were used complementary to surgery, radio-, chemo-, or targeted therapy and at least one of the following four outcomes were reported: (i) Overall survival (OS); (ii) progression-free survival (PFS); (iii) local control rate; (iv) body composition changes. Twelve papers reporting on 13 clinical studies were identified. Nine studies were prospective and six had a control group, but only two were randomized. KD prescription varied widely between studies and was described only rudimentarily in most papers. Adverse events attributed to the diet were rare and only minor (grade 1–2) except for one possibly diet-related grade 4 event. Studies reporting body composition changes found beneficial effects of KDs in both overweight and frail patient populations. Beneficial effects of KDs on OS and/or PFS were found in four studies including one randomized controlled trial. Studies in high-grade glioma patients were not sufficiently powered to prove efficacy. Evidence for beneficial effects of KDs during cancer therapy is accumulating, but more high-quality studies are needed to assess the overall strength of evidence.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    The general problems with evidence hierarchies have been thoroughly discussed. For examples see Stegenga [22] or Klement and Bandyopadhyay [23].

  2. 2.

    These two types of skepticism parallel those identified by the astronomer–philosopher Milan Ćirković regarding SETI, the search for extra-terrestrial intelligence in the Universe:”instrumentalist” (or methodological) and “fundamentalist” skepticism [29]. Indeed we argue that certain parallels can be drawn between SETI, where dogmatic principles, religious or otherwise dictate an individual’s attitude towards the endeavor, and nutrition research which is often confounded with pseudo-scientific beliefs, conflicts of interest, and dogmatism [30].

  3. 3.

    This statement is not strictly exact since the first clinical study applying a KD in cancer patients was published in 1941 and received a lot of newspaper attention. See Klement [53] for a historical review.


  1. 1.

    Cohen IA. A model for determining total ketogenic ratio (TKR) for evaluating the ketogenic property of a weight-reduction diet. Med Hypotheses. 2009;73:377–81.

  2. 2.

    Kossoff EH, Hartman AL. Ketogenic diets: new advances for metabolism-based therapies. Curr Opin Neurol. 2012;25:173–8.

  3. 3.

    Clemens Z, Tóth C. Paleolithic ketogenic diet (PKD) in chronic diseases: clinical and research data. J Evol Health. 2019;3:6.

  4. 4.

    Pérez-Guisado J, Muñoz-Serrano A, Alonso-Moraga Á. Spanish ketogenic mediterranean diet: a healthy cardiovascular diet for weight loss. Nutr J. 2008;7:30.

  5. 5.

    Klement RJ, Champ CE, Otto C, Kämmerer U. Anti-tumor effects of ketogenic diets in mice: a meta-analysis. PLoS ONE. 2016;11:e0155050.

  6. 6.

    Weber DD, Aminazdeh-Gohari S, Kofler B. Ketogenic diet in cancer therapy. Aging (Albany NY). 2018;10:164–5.

  7. 7.

    Klement RJ, Bandyopadhyay PS, Champ CE, Walach H. Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients. Theor Biol Med Model. 2018;15:12.

  8. 8.

    Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation. Cancer Metastasis Rev. 2014;33:217–29.

  9. 9.

    Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA, et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2014;2:963–70.

  10. 10.

    Klement RJ. Fasting, fats, and physics: combining ketogenic and radiation therapy against cancer. Complement Med Res. 2018;25:102–13.

  11. 11.

    Klement RJ. The influence of ketogenic therapy on the 5 R’s of radiobiology. Int J Radiat Biol. 2019;95:394–407.

  12. 12.

    Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560:499.

  13. 13.

    Martin-McGill KJ, Marson AG, Smith CT, Jenkinson MD. The modified ketogenic diet in adults with glioblastoma: an evaluation of feasibility and deliverability within the national health service. Nutr Cancer. 2018;70:643–9.

  14. 14.

    Psihogios A, Ennis JK, Seely D. Naturopathic oncology care for pediatric cancers: a practice survey. Integr Cancer Ther. 2019;18

  15. 15.

    Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr. 1988;47:42–8.

  16. 16.

    Nebeling L, Miraldi F, Shurin S, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr. 1995;14:202–8.

  17. 17.

    Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011;8:54.

  18. 18.

    Fine EJ, Segal-isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28:1028–35.

  19. 19.

    Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 2014;117:125–31.

  20. 20.

    Branca JJV, Pacini S, Ruggiero M. Effects of pre-surgical vitamin D supplementation and ketogenic diet in a patient with recurrent breast cancer. Anticancer Res. 2015;35:5525–32.

  21. 21.

    Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes. 2016;9:143.

  22. 22.

    Stegenga J. Down with the hierarchies. Topoi. 2014;33:313–22.

  23. 23.

    Klement RJ, Bandyopadhyay PS. Emergence and evidence: a close look at Bunge’s philosophy of medicine. Philosophies. 2019;4:50.

  24. 24.

    Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, et al. Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anitcancer Res. 2014;34:39–48.

  25. 25.

    Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients. Med Oncol. 2017;34:72.

  26. 26.

    Maisch P, Gschwend JE. Retz M. Wirksamkeit der ketogenen Diät bei urologischen Tumorerkrankungen: Ein systematischer Review. Urologe; 2018. p. 57.

  27. 27.

    Klement RJ, Feinman RD, Gross EC, Champ CE, D’Agostino DP, Fine EJ, et al. Need for new review of article on ketogenic dietary regimes for cancer patients. Med Oncol. 2017;34:108.

  28. 28.

    Klement RJ. Ungerechtfertigte Empfehlungen zur ketogenen Diät. Urologe. 2018;57:605–6.

  29. 29.

    Ćirković MM. Who are the SETI sceptics? Acta Astronaut. 2013;89:38–45.

  30. 30.

    Feinman RD, Keough SM. Ethics in medical research and the low-fat diet-heart hypothesis. Ethics Biol Eng Med. 2015;5:149–59.

  31. 31.

    Champ CE, Klement RJ. Commentary on “Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme”. Strahlenther Onkol. 2014;191:281–2.

  32. 32.

    Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

  33. 33.

    Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44:1843–52.

  34. 34.

    Woodhouse C, Ward T, Chaudhary R. Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization. Curr Oncol. 2019;26:433–8.

  35. 35.

    Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, et al. Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: the University of Iowa experience of two phase 1 clinical trials. Radiat Res. 2017;187:743–54.

  36. 36.

    Cohen CW, Fontaine KR, Arend RC, Alvarez RD, Leath CA III, Huh WK, et al. A Ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer. J Nutr. 2018;148:1253–60.

  37. 37.

    Ok JH, Lee H, Chung H-Y, Lee SH, Choi EJ, Kang CM, et al. The potential use of a ketogenic diet in pancreatobiliary cancer patients after pancreatectomy. Anticancer Res. 2018;38:6519–27. 10.21873/anticanres.13017

  38. 38.

    Klement RJ, Schäfer G, Sweeney RA. A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: an interim analysis of the KETOCOMP study. J Tradit Complement Med. 2019.

  39. 39.

    van der Louw EJTM, Olieman JF, van den Bemt PMLA, Bromberg JEC, Oomen-de Hoop E, Neuteboom RF, et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study. Ther Adv Med Oncol. 2019;11:1–13.

  40. 40.

    Iyikesici MS. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. Int J Hyperth. 2019;36(1):446–55.

  41. 41.

    Iyikesici MS. Long-term survival outcomes of metabolically supported chemotherapy with gemcitabine-based or FOLFIRINOX regimen combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy in metastatic pancreatic cancer. Complement Med Res. 2019;1–9

  42. 42.

    Khodabakhshi A, Akbari ME, Mirzaei HR, Mehrad-Majd H, Kalamian M, Davoodi SH. Feasibility, safety, and beneficial effects of MCT- based ketogenic diet for breast cancer treatment: a randomized controlled trial study. Nutr Cancer. 2019;1:1–8.

  43. 43.

    Furukawa K, Shigematus K, Iwase Y, Mikami W, Hoshi H, Nishiyama T, et al. Clinical effects of one year of chemotherapy with a modified medium-chain triglyceride ketogenic diet on the recurrence of stage IV colon cancer. J Clin Oncol. 2018;36:e15709.

  44. 44.

    Furukawa K, Shigematsu K, Iwase Y, Mikami W, Hoshi H, Nishiyama T, et al. Clinical effects of 1 year of chemotherapy with a modified medium-chain triglyceride ketogenic diet on the recurrence of stage IV colon cancer. J Jpn Soc Parenter Enter Nutr. 2018;33:1139–46.

  45. 45.

    Klement RJ, Sweeney RA, Gross EC, Champ CE. Problems associated with a highly artificial ketogenic diet: Letter to the Editor Re: van der Louw EJTM, Olieman JF, van den Bemt PMLA, et al. Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety. Ther Adv Med Oncol. 2019

  46. 46.

    Cohen CW, Fontaine KR, Arend RC, Gower BA. A Ketogenic diet is acceptable in women with ovarian and endometrial cancer and has no adverse effects on blood lipids: a randomized, controlled trial. Nutr Cancer 2019;

  47. 47.

    Cohen C, Fontaine K, Arend R, Soleymani T, Gower B. Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: a randomized, controlled trial. Nutrients. 2018;10:1187.

  48. 48.

    Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN. 2016;12:e1–6.

  49. 49.

    Khodabakhshi A, Akbari ME, Mirzaei HR, Kazemian E, Kalantari K, Kalamian M, et al. Effects of ketogenic diet for breast cancer treatment. a protocol for randomized controlled clinical trial. J Biochem Technol. 2018;9:90–4.

  50. 50.

    Urbain P, Bertz H. Monitoring for compliance with a ketogenic diet: what is the best time of day to test for urinary ketosis? Nutr Metab (Lond). 2016;13:77.

  51. 51.

    Volek JS, Phinney SD. The art and science oflow carbohydrate performance. 1st ed. Beyond Obesity LLC; 2012.

  52. 52.

    Howick J. The philosophy of evidence-based medicine. 1st ed. Oxford: Wiley; 2011.

  53. 53.

    Klement RJ. Wilhelm Brünings’ forgotten contribution to the metabolic treatment of cancer utilizing hypoglycemia and a very low carbohydrate (ketogenic) diet. J Tradit Complement Med. 2019;9:192–200.

  54. 54.

    Connelly J. Realism in evidence based medicine: interpreting the randomised controlled trial. J Health Organ Manag. 2004;18:70–81.

  55. 55.

    Walach H, Falkenberg T, Fønnebø V, Lewith G, Jonas WB. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol. 2006;6:29.

  56. 56.

    Mas S, Le Bonniec A, Cousson-Gèlie F. Why do women fast during breast cancer chemotherapy? A qualitative study of the patient experience. Br J Health Psychol. 2019;24:381–95.

  57. 57.

    Boros LG, Collins TQ, Somlyai G. What to eat or what not to eat—that is still the question. Neuro Oncol. 2017;19:595–6.

  58. 58.

    Klement RJ. Restricting carbohydrates to fight head and neck cancer—is this realistic? Cancer Biol Med. 2014;11:145–61.

  59. 59.

    Buse MG, Biggers JF, Friderici KH, Buse JF. Oxidation of branched chain amino acids by isolated hearts and diaphragms of the rat: the effect of fatty acids, glucose, and pyruvate respiration. J Biol Chem. 1972;247:8085–96.

  60. 60.

    Palaiologos G, Felig P. Effects of ketone bodies on amino acid metabolism in isolated rat diaphragm. Biochem J. 1976;154:709–16.

  61. 61.

    Sherwin RS, Hendler RG, Felig P. Effect of ketone infusions on amino acid and nitrogen metabolism in man. J Clin Invest. 1975;55:1382–90.

  62. 62.

    Nair KS, Welle SL, Halliday D, Campbell RG. Effect of β-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans. J Clin Invest. 1988;82:198–205.

  63. 63.

    Thomsen HH, Rittig N, Johannsen M, Møller AB, Jørgensen JO, Jessen N, et al. Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies. Am J Clin Nutr. 2018;108:857–67.

  64. 64.

    Koutnik AP, D’Agostino DP, Egan B. Anticatabolic effects of ketone bodies in skeletal muscle. Trends Endocrinol Metab. 2019;30(4):227–9.

  65. 65.

    Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer. 1987;56:39–433.

  66. 66.

    Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2:18.

  67. 67.

    Fearon KC, Tisdale MJ, Preston T, Plumb JA, Calman KC. Failure of systemic ketosis to control cachexia and the growth rate of the Walker 256 carcinosarcoma in rats. Br J Cancer. 1985;52:87–92.

  68. 68.

    Vidali S, Aminzadeh-Gohari S, Feichtinger RG, Vatrinet R, Koller A, Locker F, et al. The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer’s syndrome. Oncotarget. 2017;8:57201–15.

  69. 69.

    Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE. 2012;7:e36197.

  70. 70.

    Poff AM, Ari C, Seyfried TN, D’Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS ONE. 2013;8:e65522.

  71. 71.

    Poff AM, Ward N, Seyfried TN, Arnold P, D’Agostino DP. Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy. PLoS ONE. 2015;10:e0127407.

  72. 72.

    Morscher RJ, Aminzadeh-Gohari S, Hauser-Kronberger C, Feichtinger RG, Sperl W, Kofler B. Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model. Oncotarget. 2016;7:17060–73.

  73. 73.

    Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab. 2010;7:33.

  74. 74.

    Elsakka AMA, Bary MA, Abdelzaher E, Elnaggar M, Kalamian M, Mukherjee P, et al. Management of glioblastoma multiforme in a patient treated with ketogenic metabolic therapy and modified standard of care: a 24-month follow-up. Front Nutr. 2018;5:20.

  75. 75.

    Tóth C, Dabóczi A, Chanrai M, Schimmer M, Clemens Z. 38-Month long progression-free and symptom-free survival of a patient with recurrent glioblastoma multiforme: a case report of the paleolithic ketogenic diet (Pkd) used as a stand-alone treatment after failed standard oncotherapy. Preprints. 2019;2019120264

  76. 76.

    Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.

  77. 77.

    Hyde PN, Lustberg MB, Miller VJ, LaFountain RA, Volek JS. Pleiotropic effects of nutritional ketosis: conceptual framework for keto-adaptation as a breast cancer therapy. Cancer Treat Res Commun. 2017;12:32–9.

Download references


We thank Dr. Adeleh Khodabakhshi for providing us individual patient data from her study that allowed us to produce Figs. 2 and 3.


No funding was received for this work.

Author information

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by RJK and NB. The first draft of the manuscript was written by RJK and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Correspondence to Rainer J. Klement.

Ethics declarations

Conflict of interest

Rainer J. Klement, Nanina Brehm, and Reinhart A. Sweeney declare that they have no conflict of interest.

Ethical approval

This review was undertaken without requesting ethical approval, since ethical approval was granted for most of the included studies. All human data were anonymous, and the ethical recommendations of the Declaration of Helsinki were adhered to.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Klement, R.J., Brehm, N. & Sweeney, R.A. Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes. Med Oncol 37, 14 (2020).

Download citation


  • Cancer
  • Evidence
  • High-grade glioma
  • Ketone bodies
  • Metabolic therapy
  • Skepticism